WO2019190944A1 - Intestinal tissue enhanced with therapeutic salts - Google Patents
Intestinal tissue enhanced with therapeutic salts Download PDFInfo
- Publication number
- WO2019190944A1 WO2019190944A1 PCT/US2019/023786 US2019023786W WO2019190944A1 WO 2019190944 A1 WO2019190944 A1 WO 2019190944A1 US 2019023786 W US2019023786 W US 2019023786W WO 2019190944 A1 WO2019190944 A1 WO 2019190944A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- source
- tissue
- ions
- composition
- biomaterial
- Prior art date
Links
- 230000000968 intestinal effect Effects 0.000 title claims description 9
- 150000003839 salts Chemical class 0.000 title description 6
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 28
- 229910052796 boron Inorganic materials 0.000 claims abstract description 24
- 239000012620 biological material Substances 0.000 claims abstract description 23
- 210000001519 tissue Anatomy 0.000 claims description 101
- 238000011282 treatment Methods 0.000 claims description 37
- -1 boron ions Chemical class 0.000 claims description 29
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 26
- 210000004876 tela submucosa Anatomy 0.000 claims description 25
- 239000011574 phosphorus Substances 0.000 claims description 18
- 229910052698 phosphorus Inorganic materials 0.000 claims description 18
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 17
- 229910001431 copper ion Inorganic materials 0.000 claims description 17
- 229910052742 iron Inorganic materials 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 12
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 11
- 229910052712 strontium Inorganic materials 0.000 claims description 11
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 11
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- 239000011701 zinc Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 210000000813 small intestine Anatomy 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 7
- 229910052749 magnesium Inorganic materials 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 3
- 210000003516 pericardium Anatomy 0.000 claims description 3
- 239000005751 Copper oxide Substances 0.000 claims description 2
- 210000001691 amnion Anatomy 0.000 claims description 2
- 210000002469 basement membrane Anatomy 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229910000431 copper oxide Inorganic materials 0.000 claims description 2
- JKWMSGQKBLHBQQ-UHFFFAOYSA-N diboron trioxide Chemical compound O=BOB=O JKWMSGQKBLHBQQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 210000004379 membrane Anatomy 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 210000004303 peritoneum Anatomy 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 241001269524 Dura Species 0.000 claims 1
- 229910052810 boron oxide Inorganic materials 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 21
- 208000027418 Wounds and injury Diseases 0.000 abstract description 21
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract description 15
- 239000010949 copper Substances 0.000 abstract description 15
- 229910052802 copper Inorganic materials 0.000 abstract description 15
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract description 8
- 230000029663 wound healing Effects 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 14
- 230000001857 anti-mycotic effect Effects 0.000 description 8
- 239000002543 antimycotic Substances 0.000 description 8
- 239000012266 salt solution Substances 0.000 description 8
- 239000008151 electrolyte solution Substances 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 239000012984 antibiotic solution Substances 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 229910001425 magnesium ion Inorganic materials 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229910001415 sodium ion Inorganic materials 0.000 description 5
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910001424 calcium ion Inorganic materials 0.000 description 4
- 235000011089 carbon dioxide Nutrition 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 210000001630 jejunum Anatomy 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229910001427 strontium ion Inorganic materials 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 239000003462 bioceramic Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 239000000292 calcium oxide Substances 0.000 description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- IATRAKWUXMZMIY-UHFFFAOYSA-N strontium oxide Chemical compound [O-2].[Sr+2] IATRAKWUXMZMIY-UHFFFAOYSA-N 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- VSAISIQCTGDGPU-UHFFFAOYSA-N tetraphosphorus hexaoxide Chemical compound O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- FCPVYOBCFFNJFS-LQDWTQKMSA-M benzylpenicillin sodium Chemical class [Na+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-LQDWTQKMSA-M 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- NNIYFVYSVUWTOA-UHFFFAOYSA-N copper hydrochloride Chemical compound Cl.[Cu] NNIYFVYSVUWTOA-UHFFFAOYSA-N 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3629—Intestinal tissue, e.g. small intestinal submucosa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/22—Materials or treatment for tissue regeneration for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Definitions
- This invention relates to a composition, method, and/or system for treating tissue or biomaterial to enhance its biological and therapeutic properties; and to the use of the treated tissue or biomaterial to treat a wound or incision site.
- This invention also relates to methods for preparing the small intestinal mucosa (SIS), and the therapeutic use of the treated SIS.
- SIS small intestinal mucosa
- SIS tissue has been demonstrated to be an effective material for the treatment of wounds.
- SIS tissue contains, cytokines and mitogens which will enhance cellular ingrowth because these act as growth factors. The resultant tissue ingrowth enhances the healing rate of wounds.
- SIS tissue has been indicated to be more infection resistant than crosslinked tissues (such as glutaraldehyde tanned pericardium), its use in extreme wound cases, which often involve sepsis, merits caution. Thus, it would be
- This invention provides a SIS tissue with 1 ) enhanced tissue ingrowth properties and 2) reduced potential for infection while maintaining physical properties such that it remains useful as an implant device.
- Tissue processed in this manner will have unique properties.
- the tissue will have retained its mitogenic and cytogenic activity since these factors will be retained throughout the manufacturing process. Further, these tissues have been shown to be non-allergenic, low-allergenic, and low or non-thrombogenic.
- Tissue or biomaterial is processed, in accordance with the present invention, by exposing the tissue/biomaterial to an electrolyte solution comprising a source or boron ions and a source or copper ions.
- tissue treated as described herein exhibit added beneficial properties, including but not limited to increased resistance to infection, improved/faster healing time, and improved/faster healing quality.
- the inventor has shown that the electrolyte solution raises the pH of the extracellular (e.g., donor) tissue onto which it has been applied. The increased localized pH change inhibits microbial growth. Tissue that has been soaked in an electrolyte solution of the present invention will be infused with the elements contained in the solution. Lyophilized tissue exposed to an aqueous media will release the ions within it and subsequently the surrounding media will temporarily exhibit an elevated pH.
- tissue which has been processed in this manner contains levels of the elemental copper. Copper has been demonstrated to increase vascularization via capillary bed formation. Increased vascularization increases wound healing.
- IUD devices incorporate copper. Small amounts of copper released by these devices have been shown to be very effective in stimulating capillary bed formation. In the case of uterine endometrium, copper and stimulated capillary bed formation was sufficient to inhibit anchoring of a fertilized egg, thus preventing pregnancy.
- remodeling refers to the production of host tissue to replace implanted material and/or to the production of host tissue and structural proteins (e.g., collagen and cells) at the wound site.
- structural proteins e.g., collagen and cells
- the formulations of the present invention have been found to be antibiotic, effective against both gram -negative and gram -positive microbes; and antimycotic, effective against a broad range of fungi.
- An embodiment of the invention is a wound treatment or an implant produced using a process as described herein.
- Another embodiment is a method of treating a wound using the tissue processed as described herein.
- the method of treating a wound includes veterinary applications, e.g., treating wounds in an animal such as a dog, cat, cow, horse, or pig.
- tissue or biomaterial treated as described below may find many uses and applications, the inventor has found that the treated tissue or treated biomaterial exhibits multiple physical and biological characteristics that make it particularly suitable for treating wounds in both animals and humans.
- the present invention involves treating tissue so that the treated tissue is effective in the treatment of wounds.
- the tissue is treated with an electrolyte
- composition comprising a source or boron ions and a source of copper ions.
- An embodiment of the invention involves the use of submucosa tissue
- Suitable animal or human tissue includes but is not limited to tissues or biomaterial that contains an extracellular matrix (ECM).
- ECM extracellular matrix
- Preferred tissues or biomaterial are naturally derived collagenous ECMs isolated from human or animal sources.
- the most preferred materials and tissues are submucosa, renal capsule membrane, amnion, dura mater, pericardium, serosa, and peritoneum or basement membrane materials.
- Submucosa includes but is not limited to small intestinal submucosa (SIS), stomach mucosa, urinary bladder submucosa, or uterine submucosa, each of these derived or obtained from a human or animal.
- Submucosa tissue refers to the layer of tissue beneath a mucous membrane, or the layer of connective tissue below the tunica mucosa. It is intended that the present invention should not be limited by the source of the submucosa.
- Submucosa tissue may be found from a variety of internal organs, including but not limited to bronchi, esophagus, small intestine, large intestine, pharynx, stomach, and bladder.
- Submucosa tissue may be found in a variety of mammals, including but not limited to ovine, equine, porcine, and capeine.
- the preferred tissue is small intestine submucosa (SIS), more preferably porcine SIS.
- SIS is typically defined by the animal or source of the tissue.
- the intestine wall comprises seven layers, the outermost tissue layer which is mesenteric tissues. Layers 5-7 are sometimes referred to as the tunica mucosa, comprising layer five, the lamina muscularis mucosa (typically smooth muscle cells); layer six, the stratum compactum (typically acellular collagen and elastin fibers); and layer seven, the lamina epithelialis mucosa and its lamina basement.
- the preferred tissue is the tunica submucosa; in some embodiments, the tunica submucosa comprises layers five through seven, sometimes collectively referred to as SIS.
- the preferred source of the tissue is the jejunum, ilium, or combinations thereof.
- the tissue may be soaked in physiologic saline.
- the raw or untreated tissue may be treated to reduce its bioburden.
- Reducing bioburden includes, but is not limited to treating the tissue with an antibiotic, an antimycotic, or combinations thereof.
- the raw tissue is treated with both an antibiotic and an antimycotic.
- Allographs or allographs sources are prepared from intestinal tissue removed/obtained from donors of the same species. Heterographic sources may be used and processed as described herein from, for example, feline, canine, porcine, or bovine intestinal tissue. One skilled in the art will recognize that minimal morphological differences have been found in intestinal tissues from different species. For example, human intestinal tissue is histologically almost identical to canine intestinal tissue.
- the tissue or biomaterial may retain growth factors or other bioactive components native to the source material.
- submucosa may include one or more growth factors (e.g., FGF-2, TGF-beta, EGF, and/or PDGF); heparin, heparin sulfate; hyaluronic acid; fibronectin, as well as other growth factors or bioactive components.
- the inventor has found that using tissue from larger animals, therefore using larger tissue, may be beneficial.
- larger tissue is easier to process.
- the tissue or biomaterial can be used alone, or may be used in combination with one or more additional bioactive or pharmacological agents.
- additional agents include but are not limited to physiologically compatible minerals; growth factors; antibiotics; antimycotics; chemotherapeutic agents; antigens and/or antibodies; genetic material; enzymes; and hormones.
- tissue or SIS is used, but the invention should not be limited thereby.
- other tissues and/or biomaterial may be used in the practice of this invention.
- the submucosa tissue is harvested and cleaned using well known techniques.
- the harvested tissue is then treated with an antibiotic solution.
- the antibiotic solution as used herein, may be any solution that contains one or more antibiotics.
- the preferred solution also contains one or more antimycotics.
- Preferred antibiotics include, but are not limited to penicillin and streptomycin. Any form of antibiotic may be used, including but not limited to salts, sulfates, etc.
- Preferred antimycotics include but are not limited to amphotericin B. Any form of antimycotic may be used, including but not limited to salts, sulfates, etc.
- the tissue should be treated with the antibiotic/antimycotic solution for a sufficient period to mediate, reduce, kill, or destroy microbial function.
- the period or time required to achieve this result may vary based on the specific reagents and/or reaction conditions. The inventors have found that treating the submucosa for greater than about 15 hours is effective, but the invention should not be limited thereby.
- other treatment periods may be beneficial, typically depending on the source tissue, the source and type of antimicrobial solution(s), and the intended use of the treated tissue.
- the tissue is then soaked in solution comprising a source of boron ions and a source of copper ions. Typically this solution is an electrolyte or salt solution.
- the composition containing the boron and copper ions will be referred to as the treatment solution and the tissue will be referred to as the treated tissue.
- a treatment composition of the present invention comprises a source of boron ions, as noted above. Any source and amount of boron ions may be used.
- a preferred source of boron ions is a borate, more preferably a borate oxide.
- the amount of boron ions present in the composition may range from about 1 % to about 80%, preferably from about 30% to about 70%, more preferably from about 45% to about 60%.
- a commercially available source of boron ions comprises about 51 %, as shown in Example 1.
- a treatment composition of the present invention comprises a source of copper ions, as noted above. Any source and amount of copper ions may be used.
- a preferred source of copper ions is a soluble copper composition, more preferably a copper oxide or copper hydrochloride.
- the amount of copper ions present in the composition may range from about 0.01 % to about 5.0%, preferably from about .05% to about 3.0%, more preferably from about 0.1 % to about 1 %.
- a commercially available source of copper ions comprises about .4%, as shown in Example 1.
- any salt solution containing boron and copper may be effective within the present invention.
- the inventors have found that borate base bioceramic salt solutions are effective.
- a treatment composition of the present invention may also include additional chemical or ions.
- additional substances include but are not limited to a source of calcium; a source of potassium; a source a magnesium; a source of sodium; a source of phosphorus; ionic forms or any of the above; and oxide forms of any of the above.
- composition of the present invention may further include a source of strontium; a source of zinc; a source of iron; ionic forms of strontium, zinc, and/or iron; and oxide forms of strontium, zinc, and/or iron; and any of the ingredients listed above alone or in any combination.
- a source and amount of calcium or calcium may be used.
- a preferred source of calcium ions is a soluble calcium composition, more preferably a calcium oxide.
- the amount of calcium ions present in the composition may range from about 1 % to about 50%, preferably from about 10% to about 40%, more preferably from about 15% to about 25%.
- a commercially available source of calcium ions comprises about 20%, as shown in Example 1.
- Any source and amount of phosphorus or phosphorus ions may be used.
- a preferred source of phosphorus ions is a soluble phosphorus composition, more preferably a phosphorus oxide.
- the amount of phosphorus ions present in the composition may range from about 1 % to about 30%, preferably from about 5% to about 20%, more preferably from about 8% to about 15%.
- a commercially available source of phosphorus ions comprises about 12%, as shown in Example 1.
- a source and amount of magnesium or magnesium ions may be used.
- a preferred source of magnesium ions is a soluble magnesium composition, more preferably a magnesium oxide.
- the amount of magnesium ions present in the composition may range from about 1 % to about 20%, preferably from about 2% to about 10%, more preferably from about 3% to about 8%.
- a commercially available source of magnesium ions comprises about 5%, as shown in Example 1.
- a source and amount of sodium or sodium ions may be used.
- a preferred source of sodium ions is a soluble sodium composition, more preferably a sodium oxide.
- the amount of sodium ions present in the composition may range from about 1 % to about 20%, preferably from about 2% to about 10%, more preferably from about 3% to about 9%.
- a commercially available source of sodium ions comprises about 6%, as shown in Example 1.
- a source and amount of phosphorus or phosphorus ions may be used.
- a preferred source of phosphorus ions is a soluble phosphorus composition, more preferably a phosphorus oxide.
- the amount of phosphorus ions present in the composition may range from about 1 % to about 20%, preferably from about 2% to about 10%, more preferably from about 3% to about 7%.
- a commercially available source of phosphorus ions comprises about 4%, as shown in Example 1.
- strontium or strontium ions may be used.
- a preferred source of strontium ions is a soluble strontium composition, more preferably a strontium oxide.
- the amount of strontium ions present in the composition may range from about 0% to about 5%, preferably from about .05% to about 3%, more preferably from about .05% to about 1 %.
- a commercially available source of strontium ions comprises about .1 %, as shown in Example 1.
- a source and amount of zinc or zinc ions may be used.
- a preferred source of zinc ions is a soluble zinc composition, more preferably a zinc oxide.
- the amount of zinc ions present in the composition may range from about 0% to about 10%, preferably from about .05% to about 5%, more preferably from about .05% to about 3%.
- a commercially available source of zinc ions comprises about 1 %, as shown in Example 1 .
- a source and amount of iron or iron ions may be used.
- a preferred source of iron ions is a soluble iron composition, more preferably an iron oxide.
- the amount of iron ions present in the composition may range from about 0% to about 5%, preferably from about .05% to about 3%, more preferably from about .05% to about 1 %.
- a commercially available source of iron ions comprises about .1 %, as shown in Example 1 .
- An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of calcium or calcium ions.
- a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of calcium or calcium ions. The amount and form of the ions are described above.
- An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of potassium or potassium ions.
- a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of potassium or potassium ions. The amount and form of the ions are described above.
- An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of magnesium or magnesium ions.
- a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of magnesium or magnesium ions. The amount and form of the ions are described above.
- An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of sodium or sodium ions.
- a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of sodium or sodium ions. The amount and form of the ions are described above.
- An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of phosphorus or phosphorus ions.
- a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of phosphorus or phosphorus ions. The amount and form of the ions are described above.
- the treatment composition is mildly acidic, preferably has a pH above about 7, more preferably above about 9.
- the tissue may be soaked in or exposed to the treatment composition for a period of time sufficient to achieve the beneficial results or characteristics listed in more detail below.
- the period or time required to achieve this result may vary based on the specific reagents and/or reaction conditions. The inventors have found that a period between about one and about sixty minutes is sufficient.
- treating tissue or biomaterial with a treatment composition of the present invention provides one or more beneficial results or characteristics, including but not limited to: good or improved capillary bed formation; good, improved, or promotes native tissue to invade or remodel wound site; maintain or improves one or more ECM components; improves or maintains one or more cytokines; improves or maintains granulation; promotes granulation within about two to about three days; promotes native tissue growth at the wound site from the margin(s) toward the center; improves or maintains a collagen matrix with good or improved ECM; improves or maintains a collagen or ECM matrix with one or more epitopes for cellular
- An embodiment of the invention is tissue treated as described above and in dried form.
- An embodiment of the invention is tissue treated as described above and in powder or granulated form.
- An embodiment of the invention is a tissue or biomaterial treated with a treatment composition as described herein and formed into a sheet or patch material, including but not limited to dural or bladder patches or patching.
- the sheet or patch material may be pulverized or powderized.
- An embodiment of the invention includes a patch or patch-like material suitable for use in ophthalmic applications, including but not limited to a corneal patch.
- An embodiment of the invention includes a composition of matter and it use in neural applications, including but not limited to a sheath or covering over a nerve or nerve structure.
- a composition comprising tissue as described above may be used to treat human or animal wounds.
- a composition as described above may be used to treat other non-would conditions.
- Exemplary conditions or uses include but are not limited to treating bone defects; as a patch (e.g. a skin graft, or repair of other body tissue defects); as a wrap or covering over an incision site.
- the composition may be used to treat urinary incontinence.
- the tissue as described above is used to treat a wound.
- wounds include but are not limited to enucleation procedures, bone defects and bulking agents such as might be warranted in the treatment of urinary incontinence.
- the processes described above may further include one or more chemical or biological treatments to stabilize the tissue or biomaterial and to avoid or limit biochemical and structural degradation.
- additional treatments include but are not limited to the use of stabilizing solutions and/or solutions that prevent or reduce osmotic, hypoxic, autolytic, or proteolytic degradation; additional treatment(s) to protect against or reduce microbial contamination; and additional treatment(s) that protect against or reduce mechanical damage to the tissues or biomaterial.
- Porcine small intestine is harvested by dissecting the entire small intestine tract fresh from an appropriate animal, preferably infection-free, preferably in the 150- 200 Lb. range.
- the small intestine will measure approximately 20 feet in length.
- the jejunum of the intestine is identified and dissected away from the duodenum and ileum. While the duodenum and ileum may be processed in accordance to the teaching of this invention the jejunum is preferred.
- the jejunum is longitudinally dissected, and the mucosal lining is removed by mechanical scraping, such as with a razor blade. Care is taken not to cut the submucosa.
- the serosal surface is cleaned and separated away.
- the jejunal submucosa is then washed by immersing in isotonic saline. A minimum of three washes are recommended. Washes are conducted at room temperature with stirring. Each wash will be approximately 15 minutes in length.
- antibiotic solution consists of: 1000 gms. Saline; 1.0 gm. Penicillin sodium salt; 0.0105 gm. Amphotericin B; 0.10 gm. Streptomycin sulfate.
- the cleaned tissue is placed into the antibiotic solution at room temperature. Stirring is recommended and the tissue is processed in this manner for a minimum of 17 hours. Preparation of a treatment solution
- a salt solution is prepared using a stock salt solution of Avalon Medical's commercially available RediHeal wound treatment.
- RediHeal is a borate base
- bioceramic consisting of oxides of various salts including:
- a 10% w/w solution of electrolyte solution may be prepared by adding 100 gr. RediFleal into distilled water (900 gms.) and mixing approximately 8 hours. The resulting solution is cloudy white and is filtered to separate the particulate.
- SIS which has been cleaned and subjected to washing in an antibiotic solution in accordance to the described method is subsequently washed in a 0.9% saline solution a total of three times. Each wash is conducted for 15 minutes.
- the washed SIS tissue is immersed into the salt solution. With stirring, the SIS becomes infused with the salt solution.
- One useful ratio of SIS tissue to salt solution is: - 13 gms. (tamped) SIS /900 ml_. electrolyte solution.
- the SIS is removed from the solution and placed onto a pin frame and the tissue is mildly stretched.
- the tissue /pin frame combination is frozen to -40 F. Alternately the tissue can be frozen using dry ice.
- the tissue /pin frame is subsequently placed into a lyophilizer and the tissue is dried for a period of 2-12 hours or until such time that the tissue is dry. At this time the tissue appears white in color and is rigid in nature.
- tissue is removed from the lyophilizer, trimmed to size, placed into an appropriate container and processed for sterilization.
- the tissue may be sterilized using any suitable or known technique or process, including but not limited to ETO or electron beam radiation.
- a further useful embodiment of SIS relates to the need for the granularized or powder form of the tissue.
- Tissue harvested from an appropriate source is cleaned as previously described.
- the following steps are conducted:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is product and method for treating wounds, or enhancing wound healing, by contacting the wound with biomaterial or tissue that has been treated with a boron and copper composition.
Description
Intestinal Tissue Enhanced with Therapeutic Salts
I. Field of the Invention
[0001] This invention relates to a composition, method, and/or system for treating tissue or biomaterial to enhance its biological and therapeutic properties; and to the use of the treated tissue or biomaterial to treat a wound or incision site.
[0002] This invention also relates to methods for preparing the small intestinal mucosa (SIS), and the therapeutic use of the treated SIS.
II. Background of the Invention
[0003] Small Intestine Submucosa (SIS) tissue has been demonstrated to be an effective material for the treatment of wounds. SIS tissue contains, cytokines and mitogens which will enhance cellular ingrowth because these act as growth factors. The resultant tissue ingrowth enhances the healing rate of wounds.
[0004] One concern associated to the use of SIS relates to the potential for infection. While SIS tissue has been indicated to be more infection resistant than crosslinked tissues (such as glutaraldehyde tanned pericardium), its use in extreme wound cases, which often involve sepsis, merits caution. Thus, it would be
advantageous to prepare, provide and/or use SIS tissue that demonstrates enhanced tissue ingrowth properties and/or reduced advent of infection.
III. Summary of the Invention
[0005] This invention provides a SIS tissue with 1 ) enhanced tissue ingrowth properties and 2) reduced potential for infection while maintaining physical properties such that it remains useful as an implant device.
[0006] Tissue processed in this manner will have unique properties. In particular, the tissue will have retained its mitogenic and cytogenic activity since these factors will be retained throughout the manufacturing process. Further, these tissues have been shown to be non-allergenic, low-allergenic, and low or non-thrombogenic.
[0007] Tissue or biomaterial is processed, in accordance with the present invention, by exposing the tissue/biomaterial to an electrolyte solution comprising a source or boron ions and a source or copper ions.
[0008] The inventor has shown that tissues treated as described herein, particularly SIS tissues, exhibit added beneficial properties, including but not limited to increased resistance to infection, improved/faster healing time, and improved/faster healing quality. The inventor has shown that the electrolyte solution raises the pH of the extracellular (e.g., donor) tissue onto which it has been applied. The increased localized pH change inhibits microbial growth. Tissue that has been soaked in an electrolyte solution of the present invention will be infused with the elements contained in the solution. Lyophilized tissue exposed to an aqueous media will release the ions within it and subsequently the surrounding media will temporarily exhibit an elevated pH.
[0009] Further, tissue which has been processed in this manner contains levels of the elemental copper. Copper has been demonstrated to increase vascularization via capillary bed formation. Increased vascularization increases wound healing. For example, IUD devices incorporate copper. Small amounts of copper released by these devices have been shown to be very effective in stimulating capillary bed formation. In the case of uterine endometrium, copper and stimulated capillary bed formation was sufficient to inhibit anchoring of a fertilized egg, thus preventing pregnancy.
[0010] Also, tissue that has been processed as described herein promotes remodeling at the wound or implant site. Remodeling as used herein refers to the production of host tissue to replace implanted material and/or to the production of host tissue and structural proteins (e.g., collagen and cells) at the wound site.
[0011] The formulations of the present invention have been found to be antibiotic, effective against both gram -negative and gram -positive microbes; and antimycotic, effective against a broad range of fungi.
[0012] An embodiment of the invention is a wound treatment or an implant produced using a process as described herein.
[0013] Another embodiment is a method of treating a wound using the tissue processed as described herein. In some embodiments, the method of treating a wound
includes veterinary applications, e.g., treating wounds in an animal such as a dog, cat, cow, horse, or pig.
[0014] While the tissue or biomaterial treated as described below may find many uses and applications, the inventor has found that the treated tissue or treated biomaterial exhibits multiple physical and biological characteristics that make it particularly suitable for treating wounds in both animals and humans.
[0015] With the following enabling description of the drawings, the apparatus should become evident to a person of ordinary skill in the art.
IV. Brief Description of the Figures
[0016] Not applicable.
V. Detailed Description of the Invention
[0017] The present invention involves treating tissue so that the treated tissue is effective in the treatment of wounds. The tissue is treated with an electrolyte
composition comprising a source or boron ions and a source of copper ions.
[0018] An embodiment of the invention involves the use of submucosa tissue;
treating the submucosa tissue with one or more antibiotic agents and one or more antimycotic agents; and treating the treated tissue with an electrolyte solution as described in more detail below.
[0019] Suitable animal or human tissue includes but is not limited to tissues or biomaterial that contains an extracellular matrix (ECM). Preferred tissues or biomaterial are naturally derived collagenous ECMs isolated from human or animal sources. The most preferred materials and tissues are submucosa, renal capsule membrane, amnion, dura mater, pericardium, serosa, and peritoneum or basement membrane materials. Submucosa includes but is not limited to small intestinal submucosa (SIS), stomach mucosa, urinary bladder submucosa, or uterine submucosa, each of these derived or obtained from a human or animal.
[0020] Submucosa tissue, as used herein, refers to the layer of tissue beneath a mucous membrane, or the layer of connective tissue below the tunica mucosa. It is intended that the present invention should not be limited by the source of the
submucosa. Submucosa tissue may be found from a variety of internal organs, including but not limited to bronchi, esophagus, small intestine, large intestine, pharynx, stomach, and bladder. Submucosa tissue may be found in a variety of mammals, including but not limited to ovine, equine, porcine, and capeine.
[0021] The preferred tissue is small intestine submucosa (SIS), more preferably porcine SIS. One skilled in the art will recognize that SIS is typically defined by the animal or source of the tissue. In humans, the intestine wall comprises seven layers, the outermost tissue layer which is mesenteric tissues. Layers 5-7 are sometimes referred to as the tunica mucosa, comprising layer five, the lamina muscularis mucosa (typically smooth muscle cells); layer six, the stratum compactum (typically acellular collagen and elastin fibers); and layer seven, the lamina epithelialis mucosa and its lamina propria.
[0022] In some embodiments of the invention, the preferred tissue is the tunica submucosa; in some embodiments, the tunica submucosa comprises layers five through seven, sometimes collectively referred to as SIS.
[0023] Typically, the preferred source of the tissue is the jejunum, ilium, or combinations thereof. Upon removal from the source species, the tissue may be soaked in physiologic saline.
[0024] One skilled in the art will recognize that the raw or untreated tissue may be treated to reduce its bioburden. Reducing bioburden includes, but is not limited to treating the tissue with an antibiotic, an antimycotic, or combinations thereof.
[0025] In accordance with a preferred process of the present invention, the raw tissue is treated with both an antibiotic and an antimycotic.
[0026] Allographs or allographs sources are prepared from intestinal tissue removed/obtained from donors of the same species. Heterographic sources may be used and processed as described herein from, for example, feline, canine, porcine, or bovine intestinal tissue. One skilled in the art will recognize that minimal morphological differences have been found in intestinal tissues from different species. For example, human intestinal tissue is histologically almost identical to canine intestinal tissue.
[0027] The tissue or biomaterial may retain growth factors or other bioactive components native to the source material. For example, submucosa may include one
or more growth factors (e.g., FGF-2, TGF-beta, EGF, and/or PDGF); heparin, heparin sulfate; hyaluronic acid; fibronectin, as well as other growth factors or bioactive components.
[0028] For some embodiments, the inventor has found that using tissue from larger animals, therefore using larger tissue, may be beneficial. One skilled in the art will recognize that for some uses and treatment steps, larger tissue is easier to process.
[0029] The tissue or biomaterial can be used alone, or may be used in combination with one or more additional bioactive or pharmacological agents. Exemplary additional agents include but are not limited to physiologically compatible minerals; growth factors; antibiotics; antimycotics; chemotherapeutic agents; antigens and/or antibodies; genetic material; enzymes; and hormones.
[0030] In the disclosure that follows,“submucosa tissue” or SIS is used, but the invention should not be limited thereby. As noted above, other tissues and/or biomaterial may be used in the practice of this invention.
[0031] In accordance with the present invention, the submucosa tissue is harvested and cleaned using well known techniques. The harvested tissue is then treated with an antibiotic solution. The antibiotic solution, as used herein, may be any solution that contains one or more antibiotics. The preferred solution also contains one or more antimycotics. Preferred antibiotics include, but are not limited to penicillin and streptomycin. Any form of antibiotic may be used, including but not limited to salts, sulfates, etc.
[0032] Preferred antimycotics include but are not limited to amphotericin B. Any form of antimycotic may be used, including but not limited to salts, sulfates, etc.
[0033] The tissue should be treated with the antibiotic/antimycotic solution for a sufficient period to mediate, reduce, kill, or destroy microbial function. One skilled in the art will recognize that the period or time required to achieve this result may vary based on the specific reagents and/or reaction conditions. The inventors have found that treating the submucosa for greater than about 15 hours is effective, but the invention should not be limited thereby. One skilled in the art will recognize that other treatment periods may be beneficial, typically depending on the source tissue, the source and type of antimicrobial solution(s), and the intended use of the treated tissue.
[0034] In accordance with the present invention, the tissue is then soaked in solution comprising a source of boron ions and a source of copper ions. Typically this solution is an electrolyte or salt solution. The composition containing the boron and copper ions will be referred to as the treatment solution and the tissue will be referred to as the treated tissue.
[0035] A treatment composition of the present invention comprises a source of boron ions, as noted above. Any source and amount of boron ions may be used. A preferred source of boron ions is a borate, more preferably a borate oxide. The amount of boron ions present in the composition may range from about 1 % to about 80%, preferably from about 30% to about 70%, more preferably from about 45% to about 60%. A commercially available source of boron ions comprises about 51 %, as shown in Example 1.
[0036] A treatment composition of the present invention comprises a source of copper ions, as noted above. Any source and amount of copper ions may be used. A preferred source of copper ions is a soluble copper composition, more preferably a copper oxide or copper hydrochloride. The amount of copper ions present in the composition may range from about 0.01 % to about 5.0%, preferably from about .05% to about 3.0%, more preferably from about 0.1 % to about 1 %. A commercially available source of copper ions comprises about .4%, as shown in Example 1.
[0037] As used herein any salt solution containing boron and copper may be effective within the present invention. The inventors have found that borate base bioceramic salt solutions are effective.
[0038] A treatment composition of the present invention may also include additional chemical or ions. One skilled in the art will recognize that a wide variety and amount of additional substances may be used in the practice of this invention. Exemplary additional ingredients include but are not limited to a source of calcium; a source of potassium; a source a magnesium; a source of sodium; a source of phosphorus; ionic forms or any of the above; and oxide forms of any of the above. A treatment
composition of the present invention may further include a source of strontium; a source of zinc; a source of iron; ionic forms of strontium, zinc, and/or iron; and oxide forms of
strontium, zinc, and/or iron; and any of the ingredients listed above alone or in any combination.
[0039] Any source and amount of calcium or calcium may be used. A preferred source of calcium ions is a soluble calcium composition, more preferably a calcium oxide. The amount of calcium ions present in the composition may range from about 1 % to about 50%, preferably from about 10% to about 40%, more preferably from about 15% to about 25%. A commercially available source of calcium ions comprises about 20%, as shown in Example 1.
[0040] Any source and amount of phosphorus or phosphorus ions may be used. A preferred source of phosphorus ions is a soluble phosphorus composition, more preferably a phosphorus oxide. The amount of phosphorus ions present in the composition may range from about 1 % to about 30%, preferably from about 5% to about 20%, more preferably from about 8% to about 15%. A commercially available source of phosphorus ions comprises about 12%, as shown in Example 1.
[0041] Any source and amount of magnesium or magnesium ions may be used. A preferred source of magnesium ions is a soluble magnesium composition, more preferably a magnesium oxide. The amount of magnesium ions present in the composition may range from about 1 % to about 20%, preferably from about 2% to about 10%, more preferably from about 3% to about 8%. A commercially available source of magnesium ions comprises about 5%, as shown in Example 1.
[0042] Any source and amount of sodium or sodium ions may be used. A preferred source of sodium ions is a soluble sodium composition, more preferably a sodium oxide. The amount of sodium ions present in the composition may range from about 1 % to about 20%, preferably from about 2% to about 10%, more preferably from about 3% to about 9%. A commercially available source of sodium ions comprises about 6%, as shown in Example 1.
[0043] Any source and amount of phosphorus or phosphorus ions may be used. A preferred source of phosphorus ions is a soluble phosphorus composition, more preferably a phosphorus oxide. The amount of phosphorus ions present in the composition may range from about 1 % to about 20%, preferably from about 2% to about
10%, more preferably from about 3% to about 7%. A commercially available source of phosphorus ions comprises about 4%, as shown in Example 1.
[0044] Any source and amount of strontium or strontium ions may be used. A preferred source of strontium ions is a soluble strontium composition, more preferably a strontium oxide. The amount of strontium ions present in the composition may range from about 0% to about 5%, preferably from about .05% to about 3%, more preferably from about .05% to about 1 %. A commercially available source of strontium ions comprises about .1 %, as shown in Example 1.
[0045] Any source and amount of zinc or zinc ions may be used. A preferred source of zinc ions is a soluble zinc composition, more preferably a zinc oxide. The amount of zinc ions present in the composition may range from about 0% to about 10%, preferably from about .05% to about 5%, more preferably from about .05% to about 3%. A commercially available source of zinc ions comprises about 1 %, as shown in Example 1 .
[0046] Any source and amount of iron or iron ions may be used. A preferred source of iron ions is a soluble iron composition, more preferably an iron oxide. The amount of iron ions present in the composition may range from about 0% to about 5%, preferably from about .05% to about 3%, more preferably from about .05% to about 1 %. A commercially available source of iron ions comprises about .1 %, as shown in Example 1 .
[0047] An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of calcium or calcium ions. The amount and form of the ions are described above.
[0048] An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of potassium or potassium ions. The amount and form of the ions are described above.
[0049] An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a
source of magnesium or magnesium ions. The amount and form of the ions are described above.
[0050] An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of sodium or sodium ions. The amount and form of the ions are described above.
[0051] An embodiment of the invention includes the use of a treatment composition comprising a source of boron or boron ions, a source of copper or copper ions, and a source of phosphorus or phosphorus ions. The amount and form of the ions are described above.
[0052] In preferred embodiment of the invention, the treatment composition is mildly acidic, preferably has a pH above about 7, more preferably above about 9.
[0053] The tissue may be soaked in or exposed to the treatment composition for a period of time sufficient to achieve the beneficial results or characteristics listed in more detail below. One skilled in the art will recognize that the period or time required to achieve this result may vary based on the specific reagents and/or reaction conditions. The inventors have found that a period between about one and about sixty minutes is sufficient.
[0054] The inventor has found that treating tissue or biomaterial with a treatment composition of the present invention provides one or more beneficial results or characteristics, including but not limited to: good or improved capillary bed formation; good, improved, or promotes native tissue to invade or remodel wound site; maintain or improves one or more ECM components; improves or maintains one or more cytokines; improves or maintains granulation; promotes granulation within about two to about three days; promotes native tissue growth at the wound site from the margin(s) toward the center; improves or maintains a collagen matrix with good or improved ECM; improves or maintains a collagen or ECM matrix with one or more epitopes for cellular
attachment; promotes, maintains, or provides one or more growth factors; promotes, maintains, or provides vascularization; and promotes, stimulates, maintains, or provides cellular bed vascularization.
[0055] An embodiment of the invention is tissue treated as described above and in dried form.
[0056] An embodiment of the invention is tissue treated as described above and in powder or granulated form.
[0057] An embodiment of the invention is a tissue or biomaterial treated with a treatment composition as described herein and formed into a sheet or patch material, including but not limited to dural or bladder patches or patching. Optionally, the sheet or patch material may be pulverized or powderized.
[0058] An embodiment of the invention includes a patch or patch-like material suitable for use in ophthalmic applications, including but not limited to a corneal patch.
[0059] An embodiment of the invention includes a composition of matter and it use in neural applications, including but not limited to a sheath or covering over a nerve or nerve structure.
[0060] A composition comprising tissue as described above may be used to treat human or animal wounds.
[0061] A composition as described above may be used to treat other non-would conditions. Exemplary conditions or uses include but are not limited to treating bone defects; as a patch (e.g. a skin graft, or repair of other body tissue defects); as a wrap or covering over an incision site.
[0062] In the embodiment in which the composition is used as a bulking agent, the composition may be used to treat urinary incontinence.
[0063] In one embodiment, the tissue as described above is used to treat a wound. Examples of these wounds include but are not limited to enucleation procedures, bone defects and bulking agents such as might be warranted in the treatment of urinary incontinence.
[0064] In alternative embodiments, the processes described above may further include one or more chemical or biological treatments to stabilize the tissue or biomaterial and to avoid or limit biochemical and structural degradation. Such additional treatments include but are not limited to the use of stabilizing solutions and/or solutions that prevent or reduce osmotic, hypoxic, autolytic, or proteolytic degradation; additional treatment(s) to protect against or reduce microbial contamination; and additional
treatment(s) that protect against or reduce mechanical damage to the tissues or biomaterial.
[0065] One skilled in the art will recognize that the invention as described here may be reconfigured into different combinations, elements, and processes which are included within the scope of the invention.
[0066] The following provides exemplary methods and specific exemplary steps to illustrate the function of an apparatus and system according to the present invention
Examples
Example 1.
Porcine small intestine is harvested by dissecting the entire small intestine tract fresh from an appropriate animal, preferably infection-free, preferably in the 150- 200 Lb. range. The small intestine will measure approximately 20 feet in length. The jejunum of the intestine is identified and dissected away from the duodenum and ileum. While the duodenum and ileum may be processed in accordance to the teaching of this invention the jejunum is preferred. The jejunum is longitudinally dissected, and the mucosal lining is removed by mechanical scraping, such as with a razor blade. Care is taken not to cut the submucosa. Secondarily the serosal surface is cleaned and separated away. The jejunal submucosa is then washed by immersing in isotonic saline. A minimum of three washes are recommended. Washes are conducted at room temperature with stirring. Each wash will be approximately 15 minutes in length.
Once cleaned the washed tissue is ready to be treated with an antibiotic solution. One particularly useful antibiotic solution consists of: 1000 gms. Saline; 1.0 gm. Penicillin sodium salt; 0.0105 gm. Amphotericin B; 0.10 gm. Streptomycin sulfate.
The cleaned tissue is placed into the antibiotic solution at room temperature. Stirring is recommended and the tissue is processed in this manner for a minimum of 17 hours.
Preparation of a treatment solution
A salt solution is prepared using a stock salt solution of Avalon Medical's commercially available RediHeal wound treatment. RediHeal is a borate base
bioceramic consisting of oxides of various salts including:
Compound Percent
B2O3 51.6
CaO 20.0
K2O 12.0
MgO 5.0
Na20 6.0
P2O5 4.0
CuO 0.40 (or 0.0)
Sr 0.0 (or 0.1 )
ZnO 1.0
Fe203 0.0 (or 0.1 )
In some formulations, copper is included (CuO, 0.40 above), and the mixture does not contain Sr (0.0) or Fe203 (0.0). In other formulations, copper is not used (0.0), and both Sr (0.1 ) and Fe203 (0.1 ) are included.
A 10% w/w solution of electrolyte solution may be prepared by adding 100 gr. RediFleal into distilled water (900 gms.) and mixing approximately 8 hours. The resulting solution is cloudy white and is filtered to separate the particulate.
SIS which has been cleaned and subjected to washing in an antibiotic solution in accordance to the described method is subsequently washed in a 0.9% saline solution a total of three times. Each wash is conducted for 15 minutes.
The washed SIS tissue is immersed into the salt solution. With stirring, the SIS becomes infused with the salt solution. One useful ratio of SIS tissue to salt solution is: - 13 gms. (tamped) SIS /900 ml_. electrolyte solution.
After stirring for a period of time, e.g., 1 - 45 minutes, the SIS is removed from the solution and placed onto a pin frame and the tissue is mildly stretched. The tissue /pin frame combination is frozen to -40 F. Alternately the tissue can be frozen using dry ice.
The tissue /pin frame is subsequently placed into a lyophilizer and the tissue is dried for a period of 2-12 hours or until such time that the tissue is dry. At this time the tissue appears white in color and is rigid in nature.
Subsequently the tissue is removed from the lyophilizer, trimmed to size, placed into an appropriate container and processed for sterilization. The tissue may be sterilized using any suitable or known technique or process, including but not limited to ETO or electron beam radiation.
Example 2. Powder / Ground SIS
A further useful embodiment of SIS relates to the need for the granularized or powder form of the tissue.
Tissue harvested from an appropriate source is cleaned as previously described. In order to form a powder form of the SIS material the following steps are conducted:
• Cleaned, wet, processed tissue is macerated using a knife, razor, scissor etc. until pieces are small enough to be placed into a laboratory mill such as a Wiley mill.
• Prior to milling the small pieces are frozen w/ dry ice, or nitrogen.
• The frozen pieces in tandem with the dry ice are forced thru and past the cutting edges of the mill. The resulting pieces will shear until they can drop through the screen size of the mill. The "powder" containing a quantity of dry ice is placed into a pan which can be then re-frozen and then further processed for lyophilization. The tissue is processed until a white, granular appearance is obvious.
Subsequently the powdered tissue is packaged for sterilization via e-beam or ETG. Sterile tissue processed to form powder is useful in the treatment of wounds in which a sheet for of SIS / salt is not conducive to use.
[0100] While the invention has been described in some detail by way of illustration and example, it should be understood that the invention is susceptible to various modifications and alternative forms, and is not restricted to the specific embodiments set forth in the Examples. It should be understood that these specific embodiments are not intended to limit the invention but, on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
Claims
1. A method of treating biomaterial comprising contacting the biomaterial with a treatment composition comprising a source of boron ions and a source of copper ions.
2. The method of claim 1 wherein the source of boron ions comprises up to about 80% of the composition.
3. The method of claim 1 wherein the source of copper ions comprises up to about 5% of the composition.
4. The method of claim 1 wherein the treatment composition further comprises one or more of the following ingredients: a source of calcium; a source of potassium; a source a magnesium; a source of sodium; a source of phosphorus; ionic forms or any of the above; oxide forms of any of the above; a source of strontium; a source of zinc; a source of iron; ionic forms of strontium, zinc, or iron; oxide forms of strontium, zinc, or iron; and any of the ingredients listed above alone or in any combination.
5. The method of claim 1 or 4 wherein the treatment composition comprises a boron oxide and a copper oxide; and further comprises at least one of an oxide of calcium, potassium, magnesium, sodium, or phosphorus.
6. The method of any of claims 1 , 4, or 5 wherein the treatment composition is an electrolyte composition.
7. The method of claim 1 wherein the biomaterial is selected from the group consisting of an ECM-containing material; submucosa tissues; renal capsule
membrane; amnion; dura matter; pericardium; serosa; and peritoneum or basement membrane.
8. The method of any of claims 1 , 4, or 7 wherein the biomaterial is intestinal submucosa.
9. The method of claim 8 wherein the biomaterial is small intestine submucosa.
10. The method of any of claims 1 , 8, or 9 wherein the biomaterial is derived from an animal or human source.
11. The method of any of claims 1 4, or 5 wherein the biomaterial is contacted with an antimicrobial composition prior to contact with the treatment composition.
12. A product comprising an animal or human tissue treated with a treatment composition comprising a source of boron ions and a source of copper ions.
13. The product of claim 12 further comprising an animal or human tissue further treated with a treatment composition comprising a source of calcium; a source of potassium; a source a magnesium; a source of sodium; a source of phosphorus; ionic forms or any of the above; oxide forms of any of the above; a source of strontium; a source of zinc; a source of iron; ionic forms of strontium, zinc, or iron; oxide forms of strontium, zinc, or iron; and any of the ingredients listed above alone or in any combination.
14. The product of any of claims 12 or 13 further comprising a tissue contacted with an antimicrobial composition prior to contact with the treatment composition.
15. The product of any of claims 12-14 wherein the tissue is small intestine submucosa.
16. The use of a product produced using any of the methods of claims 1 -11 in the treatment of a wound.
17. The use of a product of any of claims 12-15 in the treatment of a wound.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19775504.4A EP3773617A4 (en) | 2018-03-24 | 2019-03-23 | Intestinal tissue enhanced with therapeutic salts |
CA3095314A CA3095314A1 (en) | 2018-03-24 | 2019-03-23 | Intestinal tissue enhanced with therapeutic salts |
US17/040,499 US20210023272A1 (en) | 2018-03-24 | 2019-03-23 | Intestinal tissue enhanced with therapeutic salts |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862647642P | 2018-03-24 | 2018-03-24 | |
US62/647,642 | 2018-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019190944A1 true WO2019190944A1 (en) | 2019-10-03 |
Family
ID=68060711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/023786 WO2019190944A1 (en) | 2018-03-24 | 2019-03-23 | Intestinal tissue enhanced with therapeutic salts |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210023272A1 (en) |
EP (1) | EP3773617A4 (en) |
CA (1) | CA3095314A1 (en) |
WO (1) | WO2019190944A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173154B2 (en) * | 2010-01-06 | 2012-05-08 | The Curators Of The University Of Missouri | Boron trioxide glass-based fibers and particles in dressings, sutures, surgical glue, and other wound care compositions |
US8415159B2 (en) * | 2008-07-30 | 2013-04-09 | Mesynthes Ltd. | Tissue scaffolds derived from forestomach extracellular matrix |
US20160325010A1 (en) * | 2013-12-10 | 2016-11-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for adhering tissue surfaces and materials and biomedical uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9502253D0 (en) * | 1995-02-06 | 1995-03-29 | Giltech Ltd | The effects of antibacterial agents on the behaviour of mouse fibroblasts in vitro |
-
2019
- 2019-03-23 US US17/040,499 patent/US20210023272A1/en not_active Abandoned
- 2019-03-23 CA CA3095314A patent/CA3095314A1/en not_active Abandoned
- 2019-03-23 EP EP19775504.4A patent/EP3773617A4/en active Pending
- 2019-03-23 WO PCT/US2019/023786 patent/WO2019190944A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415159B2 (en) * | 2008-07-30 | 2013-04-09 | Mesynthes Ltd. | Tissue scaffolds derived from forestomach extracellular matrix |
US8173154B2 (en) * | 2010-01-06 | 2012-05-08 | The Curators Of The University Of Missouri | Boron trioxide glass-based fibers and particles in dressings, sutures, surgical glue, and other wound care compositions |
US20160325010A1 (en) * | 2013-12-10 | 2016-11-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for adhering tissue surfaces and materials and biomedical uses thereof |
Non-Patent Citations (2)
Title |
---|
See also references of EP3773617A4 * |
ZHAO, S ET AL.: "Wound dressings composed of copper-doped borate bioactive glass microfibers stimulate angiogenesis and heal full-thickness skin defects in a rodent model", BIOMATERIALS, vol. 53, 2015, pages 379 - 391, XP055640547 * |
Also Published As
Publication number | Publication date |
---|---|
CA3095314A1 (en) | 2019-10-03 |
US20210023272A1 (en) | 2021-01-28 |
EP3773617A4 (en) | 2022-02-23 |
EP3773617A1 (en) | 2021-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3101739B2 (en) | Method for producing a material for osteoplasty from natural bone tissue and material obtained thereby | |
US9814744B2 (en) | Decellularized adipose cell growth scaffold | |
US7132110B2 (en) | Tissue repair compositions and methods for their manufacture and use | |
US10953044B2 (en) | Functionalized tissue matrices | |
US20210393396A1 (en) | Dermal layer for grafting having improved graft survival rate and method for producing same | |
RU2342162C1 (en) | Method for bone tissue biomaterial obtaining, and material for osteoplasty and tissue engineering obtained by such method | |
Jana et al. | Waste-derived biomaterials as building blocks in the biomedical field | |
EP0321442B1 (en) | Biologically absorbable implant material, and method for its preparation | |
WO2015012682A2 (en) | A method for extracting collagen from aquatic animals, collagen and products containing it | |
CN107427561A (en) | Skin wound therapeutic combination | |
EP2098255B1 (en) | Method for producing collagen material | |
WO2019190944A1 (en) | Intestinal tissue enhanced with therapeutic salts | |
Al-Bayati et al. | Role of acellular bovine urinary bladder submucosa on skin wound healing in Iraqi goats | |
JP7376964B2 (en) | Method for producing animal tissue-derived living tissue, animal tissue-derived living material produced thereby, and three-dimensional printing method using the same | |
DE102008013091B4 (en) | Method of making collagen material, collagen material | |
EP4069099A1 (en) | Tissue regenerative multi-drug cocktail and apparatus for delivery thereof | |
US11547780B2 (en) | Inducer for regeneration of bone and soft tissue, and method for making same and uses thereof | |
Gangwar et al. | Tissue Scaffolds Derived from Rat Skin and Clinical Applications | |
Kassem et al. | Effects of a Cellular Camel Urinary Bladder Sub Mucosa on Chronic Full Thickness Skin Wound Healing in Equine Species. | |
CN116600833A (en) | Modified pig bracket and preparation method thereof | |
CS269196B1 (en) | Biocompatible collagenous material and method of its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19775504 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3095314 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2019775504 Country of ref document: EP Effective date: 20201026 |